A5020358581- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Cardiovascular Function and Risk Factors
- Aortic Disease and Treatment Approaches
- Atrial Fibrillation Management and Outcomes
- Aortic aneurysm repair treatments
- Extracellular vesicles in disease
- Cardiac Imaging and Diagnostics
- Cardiac Structural Anomalies and Repair
- Antiplatelet Therapy and Cardiovascular Diseases
- Aortic Thrombus and Embolism
- Pulmonary Hypertension Research and Treatments
- Venous Thromboembolism Diagnosis and Management
- Endoplasmic Reticulum Stress and Disease
- Cell Adhesion Molecules Research
- Mechanical Circulatory Support Devices
- RNA modifications and cancer
- Peroxisome Proliferator-Activated Receptors
- Mitochondrial Function and Pathology
- MicroRNA in disease regulation
- Antimicrobial Resistance in Staphylococcus
- Cardiac Arrhythmias and Treatments
- Diagnosis and Treatment of Venous Diseases
- Coronary Interventions and Diagnostics
- Lipoproteins and Cardiovascular Health
Leipzig Heart Institute
2016-2025
University Medical Center of the Johannes Gutenberg University Mainz
2024-2025
Johannes Gutenberg University Mainz
2024-2025
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie
2025
Leipzig University
2012-2024
Brigham and Women's Hospital
2017-2024
Harvard University
2017-2024
University Hospital Leipzig
2017-2019
Sunnybrook Health Science Centre
2016
Health Sciences Centre
2016
Background: No pharmacological therapy exists for calcific aortic valve disease (CAVD), which confers a dismal prognosis without invasive replacement. The search therapeutics and early diagnostics is challenging because CAVD presents in multiple pathological stages. Moreover, it occurs the context of complex, multi-layered tissue architecture; rich abundant extracellular matrix phenotype; unique, highly plastic, multipotent resident cell population. Methods: A total 25 human stenotic valves...
Abstract Aims Patients with pulmonary hypertension (PHT) are often excluded from surgical therapies for tricuspid regurgitation (TR). Transcatheter valve repair (TTVR) the MitraClip™ technique is a novel treatment option these patients. We aimed to assess role of PHT in severe TR and its implications TTVR. Methods results A total 243 patients underwent TTVR at two centres. One hundred twenty-one were grouped as iPHT+ [invasive systolic artery pressures (PAPs) ≥50 mmHg]. similarly stratified...
Abstract Aims The aim of this study was to assess the pathophysiological implications severe tricuspid regurgitation (TR) in patients with heart failure preserved ejection fraction (HFpEF) by using transcatheter edge‐to‐edge repair (T‐TEER) as a model right ventricular (RV) volume overload relief. Methods and results This prospective interventional single arm trial (NCT04782908) included invasively diagnosed HFpEF. following parameters were prospectively assessed before after T‐TEER: left...
Background: Microcalcifications in atherosclerotic plaques are destabilizing, predict adverse cardiovascular events, and associated with increased morbidity mortality. 18 F-fluoride positron emission tomography (PET)/computed (CT) imaging has demonstrated promise as a useful clinical diagnostic tool identifying high-risk plaques; however, there is confusion to the underlying mechanism of signal amplification seen PET-positive, CT-negative image regions. This study tested hypothesis that...
Protein-mediated tethering of vesicles in the extracellular matrix contributes to microcalcification formation.
Tricuspid regurgitation (TR) has a poor prognosis and limited treatment options is frequently accompanied by right ventricular (RV) dysfunction. Transcatheter tricuspid valve interventions (TTVI) to reduce TR have been shown be safe feasible with encouraging early results. Patient selection for TTVI remains challenging, the role of function being unknown.The aims this study were 1) investigate survival in TTVI-treated patient population conservatively treated population, 2) evaluate outcome...
Atrial functional tricuspid regurgitation (atrial TR) has received growing recognition as a TR entity with distinct cause owing to its independence from valvular tethering the predominant mechanism underlying TR. However, characterization of atrial varies, and universal definition is lacking.In total, 651 patients significant were analyzed, including 438 conservatively treated individuals 213 who transcatheter valve repair (TTVR). Based on clustering approach, we defined (TV) tenting height...
BACKGROUND: Fewer than 50% of patients who develop aortic valve calcification have concomitant atherosclerosis, implying differential pathogenesis. Although circulating extracellular vesicles (EVs) act as biomarkers cardiovascular diseases, tissue-entrapped EVs are associated with early mineralization, but their cargoes, functions, and contributions to disease remain unknown. METHODS: Disease stage–specific proteomics was performed on human carotid endarterectomy specimens (n=16) stenotic...
Abstract Aims Calcific aortic valve disease (CAVD) is the most common disease, which consists of a chronic interplay inflammation, fibrosis, and calcification. In this study, sortilin (SORT1) was identified as novel key player in pathophysiology CAVD, its role transformation valvular interstitial cells (VICs) into pathological phenotypes explored. Methods results An (AV) wire injury (AVWI) mouse model with deficiency used to determine effects on AV stenosis, vitro experiments employed human...
Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a treatment option for patients with severe tricuspid regurgitation (TR). However, randomized trials have not shown survival benefit, possibly because of the inclusion in an early or too advanced disease stage. The authors sought to investigate association between stage and outcomes following T-TEER. In total, 1,885 significant TR were analyzed, including 585 conservatively treated individuals 1,300 who received Patients...
Aortic valvular interstitial cells (VICs) isolated from patients undergoing valve replacement are commonly used as
Calcific aortic valve disease (CAVD) occurs when subpopulations of cells undergo specific differentiation pathways, promoting tissue fibrosis and calcification. Lipoprotein particles carry oxidized lipids that promote valvular disease, but low-density lipoprotein–lowering therapies have failed in clinical trials, there are currently no pharmacological interventions available for this disease. Apolipoproteins known promoters atherosclerosis, whether they possess pathogenic properties CAVD is...
Patients undergoing transcatheter aortic valve replacement (TAVR) are often characterized by risk factors not reflected in conventional scores. In this context, little is known about the outcome of patients suffering from an active cancer disease (ACD). The objective was to determine prevalence, clinical characteristics, perioperative outcomes, and mortality with ACD TAVR compared those a history (HCD) controls without tumor disease.TAVR between 02/2006 09/2014 were stratified according...
Impaired left ventricular (LV) ejection fraction is a common finding in patients with aortic stenosis and serves as predictor of morbidity mortality after transcatheter valve replacement. However, conflicting data on the most accurate measure for LV function exist. We wanted to examine impact fraction, mean pressure gradient, stroke volume index outcome treated by replacement.Patients replacement were primarily separated into normal flow (NF; >35 mL/m2) low (LF; ≤35 mL/m2). Afterwards,...
Background Infective endocarditis ( IE ) after transcatheter aortic valve replacement is a devastating complication associated with high mortality. Our objective was to determine the impact of cardiac surgery (CS) and antibiotics - CS compared medical treatment only AB x) on 1-year mortality in patients developing replacement. Methods Results Patients were included this retrospective analysis. All-cause primary end point. A total 20 underwent 44 treated by x. In unmatched cohort, x older...